| Infect Chemother. 2021 Jun;53(2):391-394. English. Published online Jun 18, 2021. https://doi.org/10.3947/ic.2020.0154 | |
| Copyright © 2021 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS | |
|
Jerold Loh | |
|
1Division of Infectious Diseases, University Medicine Cluster, National University Health System, Singapore. | |
|
2Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. | |
|
3Division of Microbiology, Department of Laboratory Medicine, National University Health System, Singapore. | |
|
4Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Health System, Singapore. | |
*These authors contributed equally. | |
| Received December 25, 2020; Accepted April 20, 2021. | |
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by- | |
|
Abstract
| |
|
There have been recent descriptions of the novel coronavirus disease 2019 (COVID-19) presenting as ‘varicella-like exanthem’. We report three cases of patients with Varicella-Zoster Virus (VZV) and COVID-19 co-infections, presenting in three varied ways. These cases highlight the need for heightened alertness to how such co-infections can present, to pick up overlapping ‘dual pathologies’ during this current pandemic given that infection control measures including airborne precautions are crucial for both COVID-19 and VZV. |
|
Keywords:
COVID-19; Chickenpox; Coinfection; Public health; Communicable diseases
|
|
|
Introduction
|
There have been recent descriptions of the novel coronavirus disease (COVID-19) presenting with ‘varicella-like exanthema’ [1, 2]. Initial queries had been if such papulovesicular eruptions could be herpes simplex virus or varicella zoster virus (VZV) co-manifesting with COVID-19 [3, 4]; though dual simultaneous viral infections would be unusual. Herein we describe 3 patients diagnosed with VZV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infections with varying presentations.
|
Case report
|
Patient 1, 39-year-old male presented with fever and generalized pruritic vesicular rash of 3 days, in a head-to-centripetal distribution (Fig. 1A, 1B). He also tested for nasopharyngeal SARS-CoV-2 by polymerase chain reaction (PCR) (cobas SARS-CoV-2 Test; Roche Molecular Systems, Branchburg, NJ, USA) due to known exposure (Ct value- E gene: 35.76). On day 4 he deteriorated requiring supplemental oxygen. Thoracic imaging showed pulmonary nodules consistent with varicella pneumonia (Fig. 1C, 1D). The vesicular fluid tested positive for varicella DNA by PCR (VZV ELITe MGB® Kit; ELITechGroup, Puteaux, France); his sera was VZV IgM and IgG positive.
|
Patient 2, 24-year-old male presented with 2 days of fever, cough and pruritic vesicular rash, again from a head-to-centripetal distribution. He had potential COVID-19 exposure distinct from Patient 1 and was SARS-CoV-2 PCR positive (Ct value- E gene: 35.76). The vesicular fluid PCR detected varicella DNA but was negative for SARS-CoV-2.
Patient 3, 32-year-old male had fever and cough for 2 days. He was positive for SARS-CoV-2 via nasopharynx PCR (Ct value- E gene: 35.15), but developed generalized papulo-vesicular rash one week later (Fig. 1E, 1F). The patient declined vesicular and blood sampling. Primary varicella was diagnosed clinically based on classical morphological evolution and centripetal distribution.
All the patients had no common epidemiological contact. They were unacquainted; had resided and worked at different locations. All were given acyclovir with improvement. These cases beget the question whether SARS-CoV-2 infection attenuates host immunity, modulates host antiviral lymphocyte function and potentiates susceptibility to opportunistic pathogens [5]. Conversely hyperinflammatory states, recognized in SARS-CoV-2 infection [6], can be a trigger to uncover latent susceptibilities to Mycobacteria or Varicella [7, 8, 9]. However, circulating interleukin-6 incidentally measured for Patient 1 was not elevated at 8.8 pg/mL (normal 1 - 10 pg/mL).
The study was approved by the Institutional Review Board of the National Healthcare Group, Singapore (Approval number: DSRB 2021/00513). Written consent was obtained in each case for use of medical information in this report (Patient 2 declined photo documentation).
|
Discussion
|
We demonstrate the range of clinical presentations in COVID-19-VZV co-infections. Patient 1 had predominant VZV manifestation. Patient 2 had classical VZV skin lesions with upper respiratory symptom from onset. Dermatological presentation of Patient 3 was delayed, one week after COVID-19 diagnosis; similar to patients described by Marzano et al. [1].
Densely-populated locations promote co-transmission of highly infectious pathogens like SARS-CoV-2 and VZV. This can account for occurrence of co-infections epidemiologically short of invoking pathogen-evoked immunomodulation posing public health risks in living spaces like dormitories and community isolation facilities. These cases highlight the need for heightened alertness to pick up overlapping ‘dual pathologies’ during this current pandemic.
|
Notes
|
Conflict of Interest:LYAC. is an editorial board member of Infect Chemother, however, he did not involve in the peer reviewer selection, evaluation, and decision process of this article. Otherwise, no potential conflicts of interest relevant to this article was reported.
Author Contributions:
Conceptualization: JL, LYAC.
Data curation: JL, SMT, LYAC.
Investigation: JL, SMT, LYAC.
Methodology: JL, SMT, LYAC.
Project administration: JL, SMT, LYAC.
Supervision: LYAC.
Writing - original draft: JL, SMT, LYAC.
Writing - review & editing: JL, SMT, LYAC, PAT, GY, CKL.
|
Acknowledgement
|
LYAC has been supported by the Clinician Scientist Award (CSA), Individual Research Grant (IRG), Bedside & Bench (B&B) grants and the Training Fellowship Award from the National Medical, Research Council (NMRC), Singapore. He also acknowledges the Aspiration Grant, Bench to Bedside Grant and Seed Funding Grant from National University Health System, as well as funding from the National Research Foundation, Singapore.
|
References
|